Select Medical Reports Q1 Earnings and Declares Cash Dividend
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SEM?
Source: Newsfilter
- Revenue Growth: In Q1 2026, Select Medical reported a 5.0% year-over-year revenue increase to $1.4215 billion, indicating stable growth in the healthcare sector despite rising operational costs.
- Net Income Decline: The net income for Q1 was $63.8 million, down 14.7% from $74.7 million in the previous year, reflecting a decrease in operational efficiency that may impact investor confidence moving forward.
- Dividend Declaration: On April 29, 2026, the Board declared a cash dividend of $0.0625 per share, payable on May 28, 2026, demonstrating sound financial management, although the sustainability of future dividends remains uncertain.
- Merger Agreement: Select Medical entered into a merger agreement with WCAS XIV, L.P., expected to close in mid-2026, with shareholders receiving $16.50 per share in cash, marking a significant strategic shift that could affect market positioning and shareholder structure.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SEM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SEM
Wall Street analysts forecast SEM stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.490
Low
17.00
Averages
18.75
High
21.00
Current: 16.490
Low
17.00
Averages
18.75
High
21.00
About SEM
Select Medical Holdings Corporation operates critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics in the United States. Its segments include Critical Illness Recovery Hospital, Rehabilitation Hospital, and Outpatient Rehabilitation. Critical Illness Recovery Hospital segment consists of hospitals designed to serve the needs of patients recovering from critical illnesses, often with complex medical needs. It operates the majority of its critical illness recovery hospitals as a hospital within a hospital (an HIH). Rehabilitation Hospital segment serves patients that require intensive physical rehabilitation care. Outpatient Rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services. It operates around 105 critical illness recovery hospitals in 29 states, 36 rehabilitation hospitals in 14 states, and 1,922 outpatient rehabilitation clinics in 39 states and the District of Columbia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Select Medical Reports Q1 Results and Declares Cash Dividend
- Revenue Growth: In Q1 2026, Select Medical reported a 5.0% year-over-year revenue increase to $1.4215 billion, indicating stable growth in the healthcare sector despite declines in operating and net income.
- Decline in Operating Income: The operating income for Q1 was $98.4 million, down 12.7% from $112.7 million in the same quarter last year, reflecting challenges in cost control and operational efficiency that may impact future profitability.
- Cash Dividend Declaration: The Board declared a cash dividend of $0.0625 per share on April 29, 2026, payable on May 28, 2026, demonstrating the company's commitment to shareholder returns, although future dividends will depend on financial assessments.
- Merger Plan Progress: Select Medical entered into a merger agreement with WCAS XIV, L.P., expected to close in mid-2026, with shareholders receiving $16.50 per share in cash, highlighting the company's strategic intent to optimize capital structure and enhance shareholder value.
See More
Select Medical Reports Q1 Earnings and Declares Cash Dividend
- Revenue Growth: In Q1 2026, Select Medical reported a 5.0% year-over-year revenue increase to $1.4215 billion, indicating stable growth in the healthcare sector despite rising operational costs.
- Net Income Decline: The net income for Q1 was $63.8 million, down 14.7% from $74.7 million in the previous year, reflecting a decrease in operational efficiency that may impact investor confidence moving forward.
- Dividend Declaration: On April 29, 2026, the Board declared a cash dividend of $0.0625 per share, payable on May 28, 2026, demonstrating sound financial management, although the sustainability of future dividends remains uncertain.
- Merger Agreement: Select Medical entered into a merger agreement with WCAS XIV, L.P., expected to close in mid-2026, with shareholders receiving $16.50 per share in cash, marking a significant strategic shift that could affect market positioning and shareholder structure.
See More
Select Medical's Acquisition Waiting Period Ends
- Acquisition Progress: Select Medical announced that the waiting period for its acquisition by WCAS XIV, L.P. ended on April 27, 2026, with the merger expected to close in mid-2026 pending shareholder approval, indicating the company's proactive stance in the M&A market.
- Business Scale: As of March 31, 2026, Select Medical operates 103 critical illness recovery hospitals, 41 rehabilitation hospitals, and 1,912 outpatient rehabilitation clinics across 38 states and Washington D.C., showcasing its extensive influence in the healthcare sector.
- Investment Background: WCAS, a private equity firm focused on healthcare and technology, has managed over $33 billion in capital since its founding in 1979, demonstrating its strong capabilities and resource integration in the industry.
- Future Risks: Despite the smooth progress of the acquisition, Select Medical faces several risks, including the likelihood of shareholder approval, compliance issues, and market reactions, all of which could impact the company's operations and stock performance.
See More
Select Medical's Acquisition Waiting Period Concludes
- Acquisition Progress: Select Medical announced that the waiting period for its acquisition by WCAS XIV, L.P. expired on April 27, 2026, with the merger expected to close in mid-2026, pending stockholder approval, indicating proactive steps in its M&A strategy.
- Business Scale: As of March 31, 2026, Select Medical operates 103 critical illness recovery hospitals, 41 rehabilitation hospitals, and 1,912 outpatient rehabilitation clinics across 38 states and Washington D.C., highlighting its extensive footprint in the healthcare sector.
- Investment Background: WCAS is a private equity firm focused on technology and healthcare, managing over $33 billion in capital since its inception in 1979, showcasing its significant industry strength and resources.
- Future Risks: Despite the positive acquisition progress, risks remain regarding stockholder approval, regulatory reviews, and other closing conditions that could impact the finalization of the deal, necessitating close monitoring of subsequent developments.
See More
Investigation into Select Medical's $3.9 Billion Buyout
- Investigation Launched: Julie & Holleman LLP is investigating the $3.9 billion buyout of Select Medical Holdings Corp. by insiders and private equity firm Welsh Carson Anderson & Stowe, raising concerns about the fairness of the deal.
- Shareholder Rights Issues: Under the merger agreement, public shareholders of Select Medical will be cashed out at $16.50 per share, while insiders will retain ownership, potentially leading to unfair treatment for public investors.
- Legal Claim Potential: Julie & Holleman LLP has secured hundreds of millions in previous cases, indicating that they may pursue legal claims in this case to protect the interests of public shareholders.
- Market Reaction Anticipation: As insiders continue to operate the company, the market's reaction to the deal may be affected, prompting investors to monitor potential legal risks and shareholder rights concerns.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating companies including Leggett & Platt, Select Medical Holdings, KORE Group Holdings, and Forian Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Transaction Terms Scrutiny: Leggett & Platt shareholders are set to sell their shares for 0.1455 shares of Somnigroup common stock each, resulting in approximately 9% ownership of the combined company post-transaction, potentially limiting superior competing offers.
- Cash Acquisition Proposals: Select Medical shareholders will sell their shares for $16.50 each in cash, while KORE shareholders will receive $9.25 per share, with Halper Sadeh LLC possibly seeking increased consideration and other remedies to protect shareholder interests.
- Investor Rights Protection: Halper Sadeh LLC represents investors globally, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, highlighting its critical role in safeguarding investor rights.
See More
Select Medical Reports Q1 Results and Declares Cash Dividend
- Revenue Growth: In Q1 2026, Select Medical reported a 5.0% year-over-year revenue increase to $1.4215 billion, indicating stable growth in the healthcare sector despite declines in operating and net income.
- Decline in Operating Income: The operating income for Q1 was $98.4 million, down 12.7% from $112.7 million in the same quarter last year, reflecting challenges in cost control and operational efficiency that may impact future profitability.
- Cash Dividend Declaration: The Board declared a cash dividend of $0.0625 per share on April 29, 2026, payable on May 28, 2026, demonstrating the company's commitment to shareholder returns, although future dividends will depend on financial assessments.
- Merger Plan Progress: Select Medical entered into a merger agreement with WCAS XIV, L.P., expected to close in mid-2026, with shareholders receiving $16.50 per share in cash, highlighting the company's strategic intent to optimize capital structure and enhance shareholder value.
See More
Select Medical Reports Q1 Earnings and Declares Cash Dividend
- Revenue Growth: In Q1 2026, Select Medical reported a 5.0% year-over-year revenue increase to $1.4215 billion, indicating stable growth in the healthcare sector despite rising operational costs.
- Net Income Decline: The net income for Q1 was $63.8 million, down 14.7% from $74.7 million in the previous year, reflecting a decrease in operational efficiency that may impact investor confidence moving forward.
- Dividend Declaration: On April 29, 2026, the Board declared a cash dividend of $0.0625 per share, payable on May 28, 2026, demonstrating sound financial management, although the sustainability of future dividends remains uncertain.
- Merger Agreement: Select Medical entered into a merger agreement with WCAS XIV, L.P., expected to close in mid-2026, with shareholders receiving $16.50 per share in cash, marking a significant strategic shift that could affect market positioning and shareholder structure.
See More
Select Medical's Acquisition Waiting Period Ends
- Acquisition Progress: Select Medical announced that the waiting period for its acquisition by WCAS XIV, L.P. ended on April 27, 2026, with the merger expected to close in mid-2026 pending shareholder approval, indicating the company's proactive stance in the M&A market.
- Business Scale: As of March 31, 2026, Select Medical operates 103 critical illness recovery hospitals, 41 rehabilitation hospitals, and 1,912 outpatient rehabilitation clinics across 38 states and Washington D.C., showcasing its extensive influence in the healthcare sector.
- Investment Background: WCAS, a private equity firm focused on healthcare and technology, has managed over $33 billion in capital since its founding in 1979, demonstrating its strong capabilities and resource integration in the industry.
- Future Risks: Despite the smooth progress of the acquisition, Select Medical faces several risks, including the likelihood of shareholder approval, compliance issues, and market reactions, all of which could impact the company's operations and stock performance.
See More
Select Medical's Acquisition Waiting Period Concludes
- Acquisition Progress: Select Medical announced that the waiting period for its acquisition by WCAS XIV, L.P. expired on April 27, 2026, with the merger expected to close in mid-2026, pending stockholder approval, indicating proactive steps in its M&A strategy.
- Business Scale: As of March 31, 2026, Select Medical operates 103 critical illness recovery hospitals, 41 rehabilitation hospitals, and 1,912 outpatient rehabilitation clinics across 38 states and Washington D.C., highlighting its extensive footprint in the healthcare sector.
- Investment Background: WCAS is a private equity firm focused on technology and healthcare, managing over $33 billion in capital since its inception in 1979, showcasing its significant industry strength and resources.
- Future Risks: Despite the positive acquisition progress, risks remain regarding stockholder approval, regulatory reviews, and other closing conditions that could impact the finalization of the deal, necessitating close monitoring of subsequent developments.
See More
Investigation into Select Medical's $3.9 Billion Buyout
- Investigation Launched: Julie & Holleman LLP is investigating the $3.9 billion buyout of Select Medical Holdings Corp. by insiders and private equity firm Welsh Carson Anderson & Stowe, raising concerns about the fairness of the deal.
- Shareholder Rights Issues: Under the merger agreement, public shareholders of Select Medical will be cashed out at $16.50 per share, while insiders will retain ownership, potentially leading to unfair treatment for public investors.
- Legal Claim Potential: Julie & Holleman LLP has secured hundreds of millions in previous cases, indicating that they may pursue legal claims in this case to protect the interests of public shareholders.
- Market Reaction Anticipation: As insiders continue to operate the company, the market's reaction to the deal may be affected, prompting investors to monitor potential legal risks and shareholder rights concerns.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating companies including Leggett & Platt, Select Medical Holdings, KORE Group Holdings, and Forian Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Transaction Terms Scrutiny: Leggett & Platt shareholders are set to sell their shares for 0.1455 shares of Somnigroup common stock each, resulting in approximately 9% ownership of the combined company post-transaction, potentially limiting superior competing offers.
- Cash Acquisition Proposals: Select Medical shareholders will sell their shares for $16.50 each in cash, while KORE shareholders will receive $9.25 per share, with Halper Sadeh LLC possibly seeking increased consideration and other remedies to protect shareholder interests.
- Investor Rights Protection: Halper Sadeh LLC represents investors globally, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, highlighting its critical role in safeguarding investor rights.
See More
